ABVX revenueFY2025€4.57M
- FY YoY
- -63.3%
ABVX revenue was €4.57M for fiscal 2025 (ended Dec 31, 2025), down 63.3% from fiscal 2024. It rose in 2 of the last 4 fiscal years.
Abivax SA (ABVX) financials
For fiscal 2025 (ended Dec 31, 2025), Abivax SA reported €4.57M of revenue and -€336.10M of net income. Figures are in EUR, the currency of its SEC filings.
- Revenue, FY2025
- €4.57M
- Revenue growth, YoY
- -63.3%
- Net income, FY2025
- -€336.10M
- Net margin
- -7354.5%
- Free cash flow, FY2025
- -€161.27M
- EPS, diluted, FY2025
- -€4.83
- Cash
- €516.68M
FY2021FY2025
FY2021FY2025
FY2021FY2025
ABVX revenue and earnings growth
ABVX net incomeFY2025-€336.10M
ABVX net income was -€336.10M for fiscal 2025 (ended Dec 31, 2025), compared with -€176.24M in fiscal 2024.
ABVX EPSFY2025-€4.83
ABVX diluted EPS was -€4.83 for fiscal 2025 (ended Dec 31, 2025), compared with -€2.80 in fiscal 2024.
ABVX free cash flowFY2025-€161.27M
ABVX free cash flow was -€161.27M for fiscal 2025 (ended Dec 31, 2025), compared with -€154.71M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | €4.57M | €12.45M | €4.62M | €4.58M | €11.96M |
| Research and development | €177.76M | €146.53M | €103.18M | €48.30M | €47.78M |
| Selling, general and admin | €67.67M | €32.95M | €22.39M | €7.49M | €5.58M |
| Operating income | -€246.06M | -€172.98M | -€127.38M | -€64.84M | -€41.40M |
| Interest expense | €111.74M | €16.99M | €27.88M | €7.02M | €3.56M |
| Pre-tax income | -€330.25M | -€176.24M | -€147.74M | -€60.74M | -€42.45M |
| Income tax | €5.85M | €0 | €0 | €0 | €0 |
| Net income | -€336.10M | -€176.24M | -€147.74M | -€60.74M | -€42.45M |
| EPS, basic | -€4.83 | -€2.80 | -€3.43 | -€3.18 | -€2.75 |
| EPS, diluted | -€4.83 | -€2.80 | -€3.43 | -€3.18 | -€2.75 |
| Diluted shares | 69.5M | 63.0M | 43.1M | 19.1M | 15.5M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Cash and equivalents | €516.68M | €144.22M | €251.94M | €26.95M | €60.70M |
| Current assets | €551.24M | €170.67M | €285.97M | €36.18M | €75.48M |
| Goodwill | €18.42M | €18.42M | €18.42M | €18.42M | €32.01M |
| Total assets | €584.34M | €205.23M | €327.06M | €75.54M | €109.23M |
| Current liabilities | €63.02M | €94.00M | €90.69M | €51.46M | €32.27M |
| Total liabilities | €129.14M | €164.64M | €131.05M | €68.36M | €83.30M |
| Shareholders' equity | €455.20M | €40.58M | €196.01M | €7.19M | €25.93M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -€161.13M | -€154.07M | -€97.13M | -€53.94M | -€45.05M |
| Capital expenditures | €142.0K | €640.0K | €265.0K | €288.0K | €47.0K |
| Free cash flow | -€161.27M | -€154.71M | -€97.39M | -€54.22M | -€45.09M |
| Investing cash flow | -€8.19M | €15.76M | -€8.10M | -€12.03M | -€6.23M |
| Financing cash flow | €547.31M | €28.21M | €335.29M | €32.21M | €82.68M |
| Stock-based compensation | €35.40M | €20.22M | €8.18M | -€1.16M | €828.0K |
| Depreciation and amortization | €1.07M | €1.10M | €707.0K | €485.0K | €302.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue growth, YoY | -63.3% | 169.4% | 0.8% | -61.7% | - |
| Operating margin | -5384.2% | -1389.5% | -2756.5% | -1414.7% | -346.1% |
| Net margin | -7354.5% | -1415.7% | -3197.1% | -1325.3% | -354.9% |
| Free cash flow margin | -3528.9% | -1242.8% | -2107.7% | -1183.2% | -377.0% |
| Return on equity | -73.8% | -434.3% | -75.4% | -844.9% | -163.7% |
| Return on assets | -57.5% | -85.9% | -45.2% | -80.4% | -38.9% |
| Current ratio | 8.75 | 1.82 | 3.15 | 0.70 | 2.34 |
Source: XBRL data Abivax SA files with the SEC, latest filing dated Mar 23, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
ABVX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ABVX | €4.57M | -63.3% | -€336.10M | -7354.5% | $7.35B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.28T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $655.56B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $509.50B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $362.53B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $308.99B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.75B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $196.57B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.45B |
ABVX FAQ
8 questionsWhat is ABVX revenue?
Abivax SA (ABVX) reported €4.57M of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 63.3% from the year before.Is ABVX profitable?
No. Abivax SA reported a net loss of €336.10M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does ABVX have?
Abivax SA reported €516.68M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is ABVX revenue growing?
Abivax SA's revenue changed -63.3% in fiscal 2025, to €4.57M.What is ABVX free cash flow?
Abivax SA generated -€161.27M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -€161.13M less capital expenditures.What is ABVX earnings per share?
Diluted earnings per share were -€4.83 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did ABVX last report financial results?
The latest statements here come from Abivax SA's 20-F filed on Mar 23, 2026, covering the period ended Dec 31, 2025.Where does this ABVX financial data come from?
Quantisnow builds these statements from the structured XBRL data Abivax SA files with the SEC. It is provided for information only and is not investment advice.